Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented ...

Before turning to the quarter, I'd like to begin by recapping the Q1 announcements we highlighted on our last earnings call.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...

Ovarian cancer is still one of the deadliest cancers affecting women. But a new companion diagnostic is helping to change the ...

The company said it is prepared to rapidly deploy a Bundibugyo virus Ebola test if outbreak conditions require expanded diagnostic response capabilities. Key Investor Takeaways ・Co-Diagnostics (NASDAQ ...

Joint development strategy has been developed to address international deployment requirements if current outbreak continues ...

Assays need to be specific for their research purpose, be that quantifying cellular levels of specific proteins, identification of potential new drug molecules, or quantitative measurements of levels ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Please provide your email address to receive an email when new articles are posted on . A 14-gene molecular assay may help predict adjuvant chemotherapy benefit in early NSCLC. Patients assigned ...